Regulus Therapeutics Raises $20M

Carlsbad-based Regulus Therapeutics, a biopharmaceuticals firm focused on microRNA-based therapeutics, announced this morning that it has raised $20M in a Series A funding round. The investment came from Alnylam Pharmaceuticals and Isis Pharmaceuticals, which created Regulus in a joint venture in September of 2007. According to Regulus, the new funding will provide it with cash to operate through 2011. In a related move, the firm said that it has reorganized from an LLC to a C-corporation, as a way to accommodate additional future investors. Regulus also said that it now has over 900 patents focused on microRNA technology. More information »